World Antimicrobial Awareness Week 2022 – Preventing Antimicrobial Resistance Together

The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant infections. Together with private, public and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.

Antibiotic resistance can affect anyone, anywhere

Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. Millions of people suffer due to antibiotic resistance every year, and nearly 1.3 million people die. 

Anyone-anywhere-gardp-homepage

A global crisis of antibiotic resistance

Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.

Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.

Low- and middle-income countries, and certain population groups like children and the elderly, are hit hardest.

If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.

GARDP is acting now to counter drug resistance and save lives

Developing 5 new treatments
by 2025

GARDP’s “5 by 25” initiative aims to deliver five new treatments by 2025 for bacterial infections that pose the greatest threat to human health.

Access to antibiotics for patients in need around the world

GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.

Partnerships to revitalize antibiotic development

GARDP works with governments, the pharmaceutical and biotech industry, academia, and members from civil society around the world.

GARDP in the world

A global response to a global crisis